First-line panitumumab combined with FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC): data from a phase II, single-arm, multicentre study (20060314)

被引：0
|
作者：
Karthaus, M. [1 ]
Greil, R. [2 ]
Mineur, L. [3 ]
Letocha, H. [4 ]
Thaler, J. [6 ]
Hofheinz, R. [5 ]
Fernebro, E. [7 ]
Gamelin, E. [8 ]
DeCosta, L. [9 ]
Koehne, C.-H. [10 ]
机构：
[1] Klin Hamatol & Onkol, Klinikum Neuperlach, Munich, Germany
[2] Innere Med Klin 3, Salzburg, Austria
[3] Int Sainte Catherine, Avignon, France
[4] Onkol Kliniken, Vasteras, Sweden
[5] Klinikum Mannheim, Mannheim, Germany
[6] Klinikum Wels Grieskirchen, Wels, Austria
[7] Onkol Kliniken, Helsingborg, Sweden
[8] Ctr Paul Papin, Angers, France
[9] Amgen Ltd, Uxbridge, Middx, England
[10] Onkol Klinikum Oldenburg, Oldenburg, Germany
来源：
ONKOLOGIE | 2010年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：62 / 62
页数：1
相关论文
共 50 条
  • [21] Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer
    Xuetong Rong
    Haiyi Liu
    Hongmei Yu
    Jian Zhao
    Jie Wang
    Yusheng Wang
    Investigational New Drugs, 2022, 40 : 340 - 348
  • [22] Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer
    Rong, Xuetong
    Liu, Haiyi
    Yu, Hongmei
    Zhao, Jian
    Wang, Jie
    Wang, Yusheng
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (02) : 340 - 348
  • [23] Genomic alterations on first-line panitumumab plus FOLFIRI in metastatic colorectal cancer
    Avallone, Antonio
    Giuliani, Francesco
    Nasti, Guglielmo
    Montesarchio, Vincenzo
    Santabarbara, Giuseppe
    Leo, Silvana
    Malapelle, Umberto
    Rosati, Gerardo
    Lotesoriere, Claudio
    Tamburini, Emiliano
    Colombo, Alfredo
    Pepe, Francesco
    Cardone, Claudia
    Leone, Alessandra
    Vitagliano, Carlo
    Russo, Gianluca
    Troncone, Giancarlo
    Giannarelli, Diana
    De Stefano, Alfonso
    Budillon, Alfredo
    CANCER RESEARCH, 2024, 84 (06)
  • [24] Aflibercept in combination with irinotecan, fluorouracil and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal cancer (mCRC) patients: A phase II multicentric study
    Lapeyre-Prost, A.
    Pernot, S.
    Sigrand, J.
    Mary, F.
    Le Malicot, K.
    Aparicio, T.
    Dahan, L.
    Caroli-Bosc, F-X.
    Lecomte, T.
    Doat, S. Racine
    Marthey, L.
    Desrame, J.
    Lepage, C.
    Taieb, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 160 - 160
  • [25] Tumor response as important parameter during first-line treatment of metastatic colorectal carcinoma (mCRC) with panitumumab plus FOLFIRI
    Karthaus, M.
    Hofheinz, R.
    Mineur, L.
    Letocha, H.
    Greil, R.
    Thaler, J.
    Fernebro, E.
    Zhang, Y.
    Demonty, G.
    Koehne, C. -H
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 73 - 73
  • [26] Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC)
    Peeters, M.
    Price, T.
    Hotko, Y.
    Cervantes, A.
    Ducreux, M.
    Andre, T.
    Chan, E.
    Lordick, F.
    Rong, A.
    Gansert, J.
    EJC SUPPLEMENTS, 2009, 7 (03): : 10 - 10
  • [27] Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer
    Meinolf Karthaus
    Ralf-Dieter Hofheinz
    Laurent Mineur
    Henry Letocha
    Richard Greil
    Josef Thaler
    Eva Fernebro
    Kelly S Oliner
    Michael Boedigheimer
    Brian Twomey
    Ying Zhang
    Gaston Demonty
    Claus-Henning Köhne
    British Journal of Cancer, 2016, 115 : 1215 - 1222
  • [28] Interim analysis of a single-arm, phase II study of bevacizumab (BV) with modified OPTIMOX1 as first-line treatment of patients with metastatic colorectal cancer (mCRC): TCOG-GI0802
    Asano, M.
    Tanaka, S.
    Sato, A.
    Nakayama, N.
    Shimada, K.
    Konishi, K.
    Hibi, K.
    Sasaki, E.
    Kurihara, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [29] An Open-label, Single-arm, Phase 2 Trial of Panitumumab Plus FOLFIRI as Second-line Therapy in Patients with Metastatic Colorectal Cancer
    Cohn, Allen L.
    Shumaker, Grace C.
    Khandelwal, Pankaj
    Smith, David A.
    Neubauer, Marcus A.
    Mehta, Nilesh
    Richards, Donald
    Watkins, David L.
    Zhang, Kathy
    Yassine, Mohamed R.
    CLINICAL COLORECTAL CANCER, 2011, 10 (03) : 171 - 177
  • [30] Metronomic irinotecan and standard FOLFIRI regimen as first-line chemotherapy in metastatic colorectal cancer (MCRC). Final results of phase II study
    Nardi, M.
    Azzarello, D.
    Del Medico, P.
    Giannicola, R.
    Falzea, A.
    Giuffre, C.
    Maisano, R.
    Panuccio, V.
    Raffaele, M.
    Zavettieri, M.
    Avallone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345